



Large bile duct cancer significantly reduced

28-02-2011

After a few months with abdominal and lower back pain, and 6 to 10 kgs weight loss, a 62-year-old man from the Faroe Islands is diagnosed in January 2010 with what was presumably a cholangiocarcinoma (cancer of the bile ducts) with a 15 cm large tumor in left liver lobe and metastases in a big lymph node conglomerate behind the peritoneum. The patient was found inoperable and on 19.2.2010 he starts on the GOX-protocol (Gemcitabine-Oxaliplatin-Xeloda), and the patient gets the second cycle on 5.3.2010. In March, the patient moves to Jutland and continues treatment there.

In May 2010, after three cycles of treatment, a 45% reduction in the tumor is seen, thus partial remission. Treatment is continued, but in August there was no further reduction, rather a small growth, but this is interpreted as status quo. Treatment continues and on November 3rd, after 9 cycles, a CT scan reveals considerable growth in the liver and lymph nodes and additional metastases in the suprarenal glands. He is now offered, as a last option, experimental treatment with the kinase inhibitor TARCEVA and the angiogenesis inhibitor Avastin (bevacizumab) without any big documentation of this treatment's efficacy. The patient lost 4 kg from August to November. The treatment is started 8.11.2010 with 150 mg of Tarceva daily in tablet form, and Avastin 696 mg intravenously every 14 days.

On 15. November 2010 the patient arrives at Humlegaarden, where we supplement the aforementioned treatment with metronomic chemotherapy with cyclophosphamide 50 mg daily and the mistletoe compound Helixor A in increasing dosage to 100 mg every other day. Moreover, with the endorphin releaser LDN 4.5 mg daily. Furthermore, with local hyperthermia on the tumor area every other day and whole body hyperthermia. The patient continues treatment after leaving Humlegaarden on 4.12.2010, and a new CT scan on 11.1.2011 now shows pronounced size reduction in all tumor lesions, and the processes in both suprarenal glands are completely gone.

At our latest contact with the patient on February 28 2011, he feels very well, and his tumor markers are improving.

Combining Tarceva, Avastin, metronomic cyclophosphamide, Helixor and LDN is a very interesting combination, which is not only useful in connection with cholangiocarcinoma.